A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in more than 50% of patients with advSM. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate with preclinical evidence supporting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Gotlib, Jason, Baird, John H., George, Tracy I., Langford, Cheryl, Reyes, Isabel, Abuel, Justin, Perkins, Cecelia, Schroeder, Kurt, Bose, Prithviraj, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693006/
https://ncbi.nlm.nih.gov/pubmed/31350306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados